Lifecore Biomedical, Inc.
NASDAQ:LFCRDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $242.60M
- Beta
- 1.07
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$0.91
Volume 0.15M
Average 0.29M
LFCR EBITDA Margin
EBITDA as a percentage of revenue.
Lifecore Biomedical, Inc.NASDAQ: LFCR
EBITDA Margin · Q3 FY2026 · quarter ended Mar 2026
EBITDA Margin at -22.8%
EBITDA Margin was -22.8% in Q3 FY2026. On a trailing-twelve-month basis it was -0.8%. Over 3 fiscal years it narrowed by 18.4 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -0.1% for the fiscal year ending May 2026, up from -6.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -22.8%-34.1 pp QoQ
- Last fiscal yearMay 2025
- -6.8%-34.6 pp YoY
- LTMMar 2026
- -0.8%— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -34.6 pp | +6.7 pp | +41.3 pp |
| 3 years | -18.4 pp | +6.7 pp | +25.1 pp |
| 5 years | +6.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -6.8%
- Year-over-year change
- -34.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-25 | -6.8% | -34.6pp |
| FY2024 | 2024-05-26 | 27.8% | +59.9pp |
| FY2023 | 2023-05-28 | -32.1% | -43.7pp |
| FY2022 | 2022-05-29 | 11.5% | +12.5pp |
| FY2021 | 2021-05-31 | -1.0% | — |
EBITDA Margin vs competitors
How LFCR compares with its peers on the latest reported figures
- LFCR's LTM Mar 2026 EBITDA Margin of -0.8% is the 2nd highest of the 9 companies compared; the peer median is -71.8%.
- Over three fiscal years its change of -18.4 pp compares with a peer median of +98.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 3.4% | -11.6 pp | +14.0 pp | |
| LTM Mar 2026 | -0.8% | — | -18.4 pp | |
| LTM Mar 2026 | -23.8% | +18.3 pp | +37.0 pp | |
| LTM Mar 2026 | -39.8% | +16.3 pp | +70.4 pp | |
| LTM Mar 2026 | -65.7% | +112.4 pp | +874.7 pp | |
| LTM Mar 2026 | -77.8% | +9.1 pp | +98.8 pp | |
| LTM Mar 2026 | -319.0% | -184.3 pp | +1328.5 pp | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -864.8% | +3922.9 pp | — |
| FY2025 | -1246.6% | -87.2 pp | +17462.2 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding LFCR) | -71.8% | +12.7 pp | +98.8 pp | |
Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Revenue | 100.87M | 111.27M | 103.27M | 128.26M | 128.87M |
| Cost of Revenue | 61.94M | 72.2M | 75.28M | 86.41M | 88.57M |
| Gross Profit | 38.94M | 39.07M | 27.99M | 41.85M | 40.3M |
| Gross Margin | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% |
| Research & Development | 6.68M | 7.84M | 8.74M | 8.58M | 8.26M |
| Selling, General & Admin | 27.72M | 34.66M | 38.97M | 40.46M | 44.05M |
| Operating Expenses | 47.76M | 50.86M | 49.78M | 50.69M | 57.54M |
| Depreciation & Amortization | 19.87M | 18.06M | 13.18M | 8M | 8.03M |
| EBITDA | (987K) | 12.84M | (33.17M) | 35.6M | (8.81M) |
| EBITDA Margin | -1.0% | 11.5% | -32.1% | 27.8% | -6.8% |
| Operating Income | (8.82M) | (11.79M) | (21.8M) | (8.84M) | (17.25M) |
| Operating Margin | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% |
| Interest Income | 48K | 81K | 68K | 0 | 0 |
| Interest Expense | 8.93M | 15.55M | 17.65M | 18.09M | 21.84M |
| Other Income / Expenses | (20.96M) | (8.9M) | (42.13M) | 18.36M | (21.43M) |
| Income Before Tax | (29.79M) | (20.69M) | (63.93M) | 9.51M | (38.67M) |
| Pre-Tax Margin | -29.5% | -18.6% | -61.9% | 7.4% | -30.0% |
| Income Tax Expense | (6.35M) | (5.21M) | 308K | 183K | 43K |
| Net Income | (32.29M) | (116.72M) | (99.56M) | 12.01M | (38.72M) |
| Net Margin | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% |
| EPS (Basic) | (1.12) | (3.97) | (3.32) | 0.39 | (1.27) |
| EPS (Diluted) | (1.12) | (3.97) | (3.32) | 0.33 | (1.27) |
| Weighted Avg Shares | 29.29M | 29.47M | 29.96M | 30.47M | 34.82M |
| Weighted Avg Shares (Diluted) | 29.29M | 29.47M | 29.96M | 36.66M | 34.82M |
Lifecore Biomedical, Inc.
NASDAQ:LFCR
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.